

1. Cetin C, Baumgartner I. Die periphere arterielle Verschlusskrankheit (PAVK) La maladie artérielle occlusive périphérique (MAOP). *Schweiz Med Forum* 2004(4):216-223.
2. Luther M, Lepantalo M, Alback A, Matzke S. Amputation rates as a measure of vascular surgical results. *Br J Surg* 1996;**83**(2):241-4.
3. Moher D, Pham B, Ausejo M, Saenz A, Hood S, Barber GG. Pharmacological management of intermittent claudication: a meta-analysis of randomised trials. *Drugs* 2000;**59**(5):1057-70.
4. Deutsche Gesellschaft für Angiologie, Gesellschaft für Gefäßmedizin: Leitlinien zur Diagnostik und Therapie der arteriellen Verschlusskrankheit der Becken-Beinarterien, Stand Juli 2001. *VASA* 2001;**30** (Suppl. 57):1-19.
5. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). *Int Angiol* 2000;**19**(1 Suppl 1):I-XXIV, 1-304.
6. Bloor K. Natural history of arteriosclerosis of the lower extremities. *Ann R Coll Surg Engl* 1961;**28**:36-52.
7. Dormandy J, Mahir M, Ascady G, et al. Fate of the patient with chronic leg ischaemia. A review article. *J Cardiovasc Surg (Torino)* 1989;**30**(1):50-7.
8. Meijer WT, Grobbee DE, Hunink MG, Hofman A, Hoes AW. Determinants of peripheral arterial disease in the elderly: the Rotterdam study. *Arch Intern Med* 2000;**160**(19):2934-8.
9. Fowkes FG, Housley E, Riemersma RA, et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. *Am J Epidemiol* 1992;**135**(4):331-40.

10. Bainton D, Sweetnam P, Baker I, Elwood P. Peripheral vascular disease: consequence for survival and association with risk factors in the Speedwell prospective heart disease study. *Br Heart J* 1994;**72**(2):128-32.
11. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. *J Am Geriatr Soc* 1985;**33**(1):13-8.
12. Kannel WB, Skinner JJ, Jr., Schwartz MJ, Shurtleff D. Intermittent claudication. Incidence in the Framingham Study. *Circulation* 1970;**41**(5):875-83.
13. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. *N Engl J Med* 1991;**324**(17):1149-55.
14. Kannel WB, D'Agostino RB, Belanger AJ. Update on fibrinogen as a cardiovascular risk factor. *Ann Epidemiol* 1992;**2**(4):457-66.
15. Handa K, Takao M, Nomoto J, et al. Evaluation of the coagulation and fibrinolytic systems in men with intermittent claudication. *Angiology* 1996;**47**(6):543-8.
16. Libby P. Changing concepts of atherogenesis. *J Intern Med* 2000;**247**(3):349-58.
17. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. *Jama* 2001;**286**(11):1317-24.
18. Ouriel K, Zarins CK. Doppler ankle pressure: an evaluation of three methods of expression. *Arch Surg* 1982;**117**(10):1297-1300.
19. Empfehlungen zur Therapie der peripheren arteriellen Verschlusskrankheit (pAVK). *Arzneiverordnung in der Praxis* 2003;**30**(Sonderheft 3 (Therapieempfehlungen)).

-
20. Hirsch AT, Treat-Jacobson D, Lando HA, Hatsukami DK. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. *Vasc Med* 1997;**2**(3):243-51.
 21. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. *Jama* 1999;**282**(16):1523-9.
 22. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. *N Engl J Med* 2002;**347**(24):1941-51.
 23. Baumgartner I, Schainfeld R, Graziani L. Management of Peripheral Vascular Disease. *Annu Rev Med* 2005;**56**:249-272.
 24. DeWeese JA, Leather R, Porter J. Practice guidelines: lower extremity revascularization. *J Vasc Surg* 1993;**18**(2):280-94.
 25. de Vries SO, Hunink MG. Results of aortic bifurcation grafts for aortoiliac occlusive disease: a meta-analysis. *J Vasc Surg* 1997;**26**(4):558-69.
 26. Dotter CT, Judkins MP. Transluminal Treatment of Arteriosclerotic Obstruction. Description of a New Technic and a Preliminary Report of Its Application. *Circulation* 1964;**30**:654-70.
 27. Gruntzig A, Hirzel H, Goebel N, et al. [Percutaneous transluminal dilatation of chronic coronary stenoses. First experiences]. *Schweiz Med Wochenschr* 1978;**108**(44):1721-3.
 28. Kaufmann, Moser, Sauer. Radiologie. 2. erweiterte Auflage ed. München Jena: Urban & Fischer, Oktober 2001.
 29. Reiser M, Kuhn F-P, Debus J. Radiologie. Stuttgart: Georg Thieme Verlag, 2004.

30. Pentecost MJ, Criqui MH, Dorros G, et al. Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels. A statement for health professionals from a Special Writing Group of the Councils on Cardiovascular Radiology, Arteriosclerosis, Cardio-Thoracic and Vascular Surgery, Clinical Cardiology, and Epidemiology and Prevention, the American Heart Association. *J Vasc Interv Radiol* 2003;**14**(9 Pt 2):S495-515.
31. Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. *Radiology* 1997;**204**(1):87-96.
32. Roth F-J, Scheffler A, Krings W, Grün B, Barthen I. Ballonangioplastie peripherer Gefäße. In: Günther RW, Thelen M, eds. Interventionelle Radiologie. 2. vollständig überarbeitete und erweiterte Auflage ed. Stuttgart: Georg Thieme Verlag, 1999: 81-97.
33. Gupta AK, Ravimandalam K, Rao VR, et al. Total occlusion of iliac arteries: results of balloon angioplasty. *Cardiovasc Intervent Radiol* 1993;**16**(3):165-77.
34. Jorgensen B, Skovgaard N, Norgard J, Karle A, Holstein P. Percutaneous transluminal angioplasty in 226 iliac artery stenoses: role of the superficial femoral artery for clinical success. *Vasa* 1992;**21**(4):382-6.
35. Tegtmeyer CJ, Hartwell GD, Selby JB, Robertson R, Jr., Kron IL, Tribble CG. Results and complications of angioplasty in aortoiliac disease. *Circulation* 1991;**83**(2 Suppl):I53-60.
36. Stokes KR, Strunk HM, Campbell DR, Gibbons GW, Wheeler HG, Clouse ME. Five-year results of iliac and femoropopliteal angioplasty in diabetic patients. *Radiology* 1990;**174**(3 Pt 2):977-82.

37. Johnston KW. Iliac arteries: reanalysis of results of balloon angioplasty. *Radiology* 1993;**186**(1):207-12.
38. Soder HK, Manninen HI, Rasanen HT, Kaukanen E, Jaakkola P, Matsi PJ. Failure of prolonged dilation to improve long-term patency of femoropopliteal artery angioplasty: results of a prospective trial. *J Vasc Interv Radiol* 2002;**13**(4):361-9.
39. Cejna M, Thurnher S, Illiasch H, et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. *J Vasc Interv Radiol* 2001;**12**(1):23-31.
40. Karch LA, Mattos MA, Henretta JP, McLafferty RB, Ramsey DE, Hodgson KJ. Clinical failure after percutaneous transluminal angioplasty of the superficial femoral and popliteal arteries. *J Vasc Surg* 2000;**31**(5):880-7.
41. Matsi PJ, Manninen HI, Vanninen RL, et al. Femoropopliteal angioplasty in patients with claudication: primary and secondary patency in 140 limbs with 1-3-year follow-up. *Radiology* 1994;**191**(3):727-33.
42. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. *N Engl J Med* 1987;**316**(12):701-6.
43. Jahnke T, Voshage G, Muller-Hulsbeck S, Grimm J, Heller M, Brossmann J. Endovascular placement of self-expanding nitinol coil stents for the treatment of femoropopliteal obstructive disease. *J Vasc Interv Radiol* 2002;**13**(3):257-66.
44. Murphy TP, Ariaratnam NS, Carney WI, Jr., et al. Aortoiliac insufficiency: long-term experience with stent placement for treatment. *Radiology* 2004;**231**(1):243-9.

45. Schurmann K, Mahnken A, Meyer J, et al. Long-term results 10 years after iliac arterial stent placement. *Radiology* 2002;**224**(3):731-8.
46. Lammer J, Dake MD, Bleyen J, et al. Peripheral arterial obstruction: prospective study of treatment with a transluminally placed self-expanding stent-graft. International Trial Study Group. *Radiology* 2000;**217**(1):95-104.
47. Sullivan TM, Childs MB, Bacharach JM, Gray BH, Piedmonte MR. Percutaneous transluminal angioplasty and primary stenting of the iliac arteries in 288 patients. *J Vasc Surg* 1997;**25**(5):829-38; discussion 838-9.
48. Vorwerk D, Gunther RW, Schurmann K, Wendt G. Aortic and iliac stenoses: follow-up results of stent placement after insufficient balloon angioplasty in 118 cases. *Radiology* 1996;**198**(1):45-8.
49. Henry M, Amor M, Ethevenot G, et al. Palmaz stent placement in iliac and femoropopliteal arteries: primary and secondary patency in 310 patients with 2-4-year follow-up. *Radiology* 1995;**197**(1):167-74.
50. Vorwerk D, Guenther RW, Schurmann K, Wendt G, Peters I. Primary stent placement for chronic iliac artery occlusions: follow-up results in 103 patients. *Radiology* 1995;**194**(3):745-9.
51. Cikrit DF, Gustafson PA, Dalsing MC, et al. Long-term follow-up of the Palmaz stent for iliac occlusive disease. *Surgery* 1995;**118**(4):608-13; discussion 613-4.
52. Jahnke T, Andresen R, Muller-Hulsbeck S, et al. Hemobahn stent-grafts for treatment of femoropopliteal arterial obstructions: midterm results of a prospective trial. *J Vasc Interv Radiol* 2003;**14**(1):41-51.

-
53. Strecker EP, Boos IB, Gottmann D. Femoropopliteal artery stent placement: evaluation of long-term success. *Radiology* 1997;**205**(2):375-83.
54. White GH, Liew SC, Waugh RC, et al. Early outcome and intermediate follow-up of vascular stents in the femoral and popliteal arteries without long-term anti-coagulation. *J Vasc Surg* 1995;**21**(2):270-9; discussion 279-81.
55. Gray BH, Sullivan TM, Childs MB, Young JR, Olin JW. High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty. *J Vasc Surg* 1997;**25**(1):74-83.
56. Bray AE, Liu WG, Lewis WA, Harrison C, Maullin A. Strecker stents in the femoropopliteal arteries: value of duplex ultrasonography in restenosis assessment. *J Endovasc Surg* 1995;**2**(2):150-60.
57. Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. *Circulation* 2002;**106**(12):1505-9.
58. Kearney M, Pieczek A, Haley L, et al. Histopathology of in-stent restenosis in patients with peripheral artery disease. *Circulation* 1997;**95**(8):1998-2002.
59. Davies MG, Hagen PO. Pathobiology of intimal hyperplasia. *Br J Surg* 1994;**81**(9):1254-69.
60. Carrel A, Guthrie CC. Anastomosis of blood vessels by the patching method and transplantation of the kidney. 1906 [classical article]. *Yale J Biol Med* 2001;**74**(4):243-7.

61. Schillinger M, Exner M, Mlekusch W, et al. Vascular inflammation and percutaneous transluminal angioplasty of the femoropopliteal artery: association with restenosis. *Radiology* 2002;**225**(1):21-6.
62. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. *J Am Coll Cardiol* 1998;**31**(1):224-30.
63. Inoue S, Koyama H, Miyata T, Shigematsu H. Pathogenetic heterogeneity of in-stent lesion formation in human peripheral arterial disease. *J Vasc Surg* 2002;**35**(4):672-8.
64. Carlier SG, van Damme LC, Blommerde CP, et al. Augmentation of wall shear stress inhibits neointimal hyperplasia after stent implantation: inhibition through reduction of inflammation? *Circulation* 2003;**107**(21):2741-6.
65. Sullivan TM, Ainsworth SD, Langan EM, et al. Effect of endovascular stent strut geometry on vascular injury, myointimal hyperplasia, and restenosis. *J Vasc Surg* 2002;**36**(1):143-9.
66. de Feyter PJ, Vos J, Rensing BJ. Anti-restenosis Trials. *Curr Interv Cardiol Rep* 2000;**2**(4):326-331.
67. Minar E, Pokrajac B, Maca T, et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty : results of a prospective randomized study. *Circulation* 2000;**102**(22):2694-9.
68. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. *N Engl J Med* 2002;**346**(23):1773-80.

-
69. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. *N Engl J Med* 2003;**348**(16):1537-45.
70. Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. *J Vasc Interv Radiol* 2005;**16**(3):331-8.
71. Rowinsky EK, Donehower RC. Paclitaxel (taxol). *N Engl J Med* 1995;**332**(15):1004-14.
72. Kojda G. Pharmaka zur Behandlung von Tumorerkrankungen (Zytostatika). In: Kojda G, ed. *Pharmakologie/Toxikologie systematisch*. Bremen: UNI-MED, 2002: 781-783.
73. Spencer CM, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. *Drugs* 1994;**48**(5):794-847.
74. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. *Circulation* 1997;**96**(2):636-45.
75. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. *Circulation* 2001;**103**(18):2289-95.
76. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. *Circulation* 2001;**104**(4):473-9.
77. Scheller B, Speck U, Schmitt A, Bohm M, Nickenig G. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. *J Am Coll Cardiol* 2003;**42**(8):1415-20.

-
78. Strotmann JM, Bauersachs J, Fraccarollo D, et al. Trauma induced by nontraumatic coronary devices and its impact on vascular reactivity and morphology. *Am J Physiol Heart Circ Physiol* 2002;**283**(6):H2356-62.
79. Scheller B, Speck U, Romeike B, et al. Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model. *Eur Heart J* 2003;**24**(15):1462-7.
80. Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. *Circulation* 2004;**110**(7):810-4.
81. Drachman DE, Edelman ER, Seifert P, et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. *J Am Coll Cardiol* 2000;**36**(7):2325-32.
82. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. *Circulation* 1996;**94**(7):1690-7.
83. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. *J Am Coll Cardiol* 2006;**48**(12):2584-91.
84. Lovich MA, Creel C, Hong K, Hwang CW, Edelman ER. Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. *J Pharm Sci* 2001;**90**(9):1324-35.
85. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. *N Engl J Med* 2006;**355**(20):2113-24.

86. Speck U, Scheller B, Abramjuk C, Grossmann S, Mahnkopf D, Simon O. Inhibition of restenosis in stented porcine coronary arteries: uptake of Paclitaxel from angiographic contrast media. *Invest Radiol* 2004;**39**(3):182-6.
87. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. *Circulation* 2001;**104**(10):1188-93.
88. Duda SH, Poerner TC, Wiesinger B, et al. Drug-eluting stents: potential applications for peripheral arterial occlusive disease. *J Vasc Interv Radiol* 2003;**14**(3):291-301.
89. Cho L, Roffi M, Mukherjee D, Bhatt DL, Bajzer C, Yadav JS. Superficial femoral artery occlusion: nitinol stents achieve better flow and reduce the need for medications than balloon angioplasty alone. *J Invasive Cardiol* 2003;**15**(4):198-200.
90. Waksman R, Ajani AE, White RL, et al. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS). *Circulation* 2001;**103**(19):2332-5.
91. Farb A, Shroff S, John M, Sweet W, Virmani R. Late arterial responses (6 and 12 months) after (32)P beta-emitting stent placement: sustained intimal suppression with incomplete healing. *Circulation* 2001;**103**(14):1912-9.
92. Kay IP, Wardeh AJ, Kozuma K, et al. Radioactive stents delay but do not prevent in-stent neointimal hyperplasia. *Circulation* 2001;**103**(1):14-7.
93. Carter AJ, Laird JR, Farb A, Kufs W, Wortham DC, Virmani R. Morphologic characteristics of lesion formation and time course of smooth muscle cell

- proliferation in a porcine proliferative restenosis model. *J Am Coll Cardiol* 1994;**24**(5):1398-405.
94. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. *Circulation* 1999;**99**(1):44-52.
95. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. *J Am Coll Cardiol* 2004;**44**(7):1373-85.